Cordis 2.25 mm CYPHER Sirolimus-Eluting Stent Approved for Coronaries

 

September 22, 2009

Cordis Corp. offers the 2.25 mm CYPHER Sirolimus-Eluting Coronary Stent, which is indicated for treatment of coronary blockages in small vessels.

Many types of patients have small vessel disease, including women and those with certain other medical conditions. Small coronary vessels have been associated with an increased risk of re-blockage (restenosis) after stent implantation, which requires another procedure to reopen the vessel. The smaller the artery, the more the regrowth of cells within a stent, and stent recoil narrow the lumen. This accentuates the clinical benefits of the CYPHER Stent, which is unsurpassed in limiting this process.

The stent was cleared by the FDA in September 2009.

For more information: www.cypherstent.com, www.cordis.com